Predicted Nivolumab Exposures (Cavg1 and Cavgss) at 480 mg Q4W (Relatlimab Plus Nivolumab) by Body Weight Quartiles in Adult 1L MEL
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: